Drawing for QIASEQ

USPTO serial 79201919

QIASEQ

Reviewed by CopyMark Law Group

Reg. 5288349Status 739Renewal
Filing date
Status date
Registration date
Sep 19, 2017
Examiner
LAM, HAI-LY HUYNH
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with QIASEQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Victoria Friedman

Victoria Friedman Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes; non-medical reagents, enzymes and buffer solutions for scientific and/or medical research use, namely, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for scientific or medical research use; kits comprising chemicals for sample preparation, modification and manipulation of cells for scientific purposes, other than for medical or veterinary use; kits comprising chemicals for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material all for scientific purposes, other than for medical or veterinary use; kits comprising in particular chemicals for reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing for scientific purposes, other than for medical or veterinary useACTIVE—
005Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical or veterinary purposes; chemical, biochemical and biotechnological preparations, in particular reagents, enzymes and buffer solutions for medical or veterinary purposes, namely, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical or veterinary purposes; kits containing preparations of reagents, enzymes and buffer solutions for medical and veterinary diagnostic purposes, in particular for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing all for medical and veterinary diagnostic purposesACTIVE—
009Scientific apparatuses, instruments and devices, as well as their structural replacement parts and components, namely, laboratory devices for detecting genetic sequences, laboratory apparatus and instruments for extracting, isolating, separating, purifying, duplicating, sequencing and/or analyzing biopolymers, in particular, nucleic acids, proteins, DNA macromolecules and biologically active substances, electrical equipment for the genetic modification of cells for research purposes; software for use in scientific and medical research, namely, software for scientific analysis of genetic sequences; software for analysis of nucleic acids, in particular software for sequencing of nucleic acids, software for extracting, isolating, separating, purifying, duplicating, sequencing and/or analyzing biopolymers, in particular, nucleic acids, proteins, DNA macromolecules and biologically active substancesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 1, 2026RNWLINTERNATIONAL REGISTRATION RENEWED—
Sep 19, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Apr 24, 2024NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Apr 24, 2024C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Apr 23, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 30, 2023ES75TEAS SECTION 71 & 15 RECEIVED—
Sep 19, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
May 14, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 10, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 12, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 12, 2018FIMPFINAL DISPOSITION PROCESSED—
Dec 19, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 19, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 4, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 4, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 14, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 27, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 23, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 13, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 13, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 13, 2017ALIEASSIGNED TO LIE—
Apr 21, 2017ALIEASSIGNED TO LIE—
Apr 6, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 25, 2017RFNTREFUSAL PROCESSED BY IB—
Mar 14, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 14, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 4, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 4, 2017RFRRREFUSAL PROCESSED BY MPU—
Mar 3, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 2, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 28, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 24, 2017DOCKASSIGNED TO EXAMINER—
Feb 24, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 23, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance